Body Fat as Determinant of Female Gonadal Dysfunction

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-40
SponsorFundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

About this trial

Reproduction requires from women enough energy depots to warrant an adequate nutritional supply to the fetus. Hence, adipose tissue is able to communicate with female hypothalamic-pituitary-ovary axis. The hypothesis of the project is that abnormalities in the quantity (absolute and relative to lean body mass), distribution and/or function of adipose tissue are associated with functional forms of female gonadal dysfunction in predisposed women, in a spectrum of anomalies that go from hypothalamic amenorrhea to the polycystic ovary syndrome (PCOS). To challenge this hypothesis, the investigators will study 5 groups of 10 women each: women with exercise-associated hypothalamic amenorrhea, women without ovulatory dysfunction that exercise equally, non-hyperandrogenic patients with PCOS, hyperandrogenic patients with PCOS, and healthy control women comparable to those with PCOS. The aims of the study will be:

Primary objective: To identify novel signalling factors originating from adipose tissue and muscle using targeted and nontargeted evaluation of the proteome and of gene expression of superficial subcutaneous fat, deep subcutaneous fat (which mimics visceral adipose tissue) and skeletal muscle.

Secondary objectives:

1. To study the serum adipokine profile - including those identified by the primary objective - and circulating gut hormones during fasting and after a glucose load in the 5 groups of women, and their associations with sexual hormones and body fat distribution. 2. To study body composition and body fat distribution in these women and their relationships with:

2.1, Sex steroid profiles.

2.2. Classic cardiovascular risk factors: carbohydrate metabolism, lipid profiles and blood pressure.

2.3 Markers of low-grade chronic inflammation.

2.4. Oxidative stress markers.

2.5. Cardiovascular autonomic function.

2.6. Surrogate markers of subclinical atherosclerosis.

2.7. Circulating concentrations of endocrine disruptors.

2.8. Oral and gut microbiome.

The results will provide a better understanding of the mechanisms linking body energy depots with the female reproductive axis and, hopefully, the identification of potential biomarkers for the diagnosis and treatment of the disorders studied here.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Body mass index between 18.5 and 25.0 kg/m2.

Group 1 ovulatory dysfunction [World Health Organization (WHO) classification].

Normal/low gonadotrophin levels [follicle-stimulating hormone (FSH) and luteinizing (LH) < 10 IU/l] and low estradiol (< 50 pg/ml).

Moderate-vigorous intensity physical activity (> 5 hours per week) plus low energy availability (< 30 kcal/per kg of lean mass).

Disqualifiers

Oral drugs interfering with ovulation (glucocorticoids, antipsychotics, antidepressants, contraceptives, sex steroids and/or opioids) for the previous 6 months to study inclusion.

Current pregnancy or lactation, or during the previous 6 months to study inclusion.

Asherman's syndrome or outflow tract disorders.

Current smoking or alcohol intake > 40 g per day.

Trial population

Patients with exercise-associated functional amenorrhea and polycystic ovary syndrome will be consecutively recruited from our Reproductive Endocrinolgy clinic. Those premenopausal adult women are referred to clinic because of symptoms of functional androgen excess such as hirsutism or menstrual dysfunction. The control group (Groups IV and V) will include healthy female volunteers recruited - contemporarily with the recruitment of patients - from the hospital's staff and overweight or obese women seeking medical attention in our department.

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

  • Anthropometric and physical examination

    Diagnostic test

    * Weight and height. * Waist-to-hip ratio. * Body composition: Bioelectrical impedance and \[Dual energy X-ray absorptiometry (DEXA)\].

  • Indirect calorimetry, accelerometer and seven-day dietary recall

    Diagnostic test

    Energy availability assessment.

  • Biochemical, hormonal and metabolic phenotyping

    Diagnostic test

    * Lipid profile. * Oral glucose tolerance test: plasma glucose and insulin, insulin sensitivity indices, gastrointestinal hormones, adipokines, oxidative stress markers. * Sex steroid profile. * Hypothalamic-pituitary-adrenal axis study. * Ferrokinetic study. * Subclinical chronic inflammatory markers.

  • Sonographic studies

    Diagnostic test

    * Polycystic ovarian morphology. * Carotid intima-media thickness. * Eco-FAT: Ultrasound measurements of adipose tissue depots including sc, preperitoneal, intraperitoneal (ip), mesenteric, and perirenal fat thickness.

  • 24-hour Ambulatory blood pressure monitoring

    Diagnostic test

    A\&D TM2430EX oscillometric devices (A\&D Company Limited, Tokyo, Japan).

  • Percutaneous biopsy

    Procedure/Surgery

    Subcutaneous fat tissue and muscle tissue for proteomics an gene expression studies.

  • Cardiovascular autonomic function studies

    Diagnostic test

    Parasympathetic and sympathetic responses to deep breathing, Valsalva's maneuver and orthostatism.

  • Oral smear and feces specimen

    Diagnostic test

    Microbiome studies.

Treatment groups

50 Participants
are divided into 5 treatment groups
Group A: I- Hypothalamic amenorrhea8 interventions
Group B: II- Hyperandrogenic polycystic ovary syndrome8 interventions
Group C: III- Non-hyperandrogenic polycystic ovary syndrome8 interventions
Group D: IV- Trained women without ovulatory dysfunction8 interventions
Group E: V- Non-hyperandrogenic healthy women8 interventions

Trial outcomes

Primary outcomes

1

Adipokine and myokine signaling identification

Time frame
Up to 5 years

Secondary outcomes

1

Circulating adipokine profile

At fasting and after an oral glucose challenge: Circulating concentrations of Leptin, Adiponectin, Chemerin, Lipocalin-2, Adipsin, Plasminogen Activator Inhibitor (PAI)-1, Monocyte Chemoattractant Protein (MCP)-1, and Soluble Leptin Receptor by multianalyte profiling on the Luminex Magpix system (Luminex Technologies, Austin, USA.).

Time frame
Up to 5 years
2

Appetite regulation hormonal profile

At fasting and after an oral glucose challenge: Circulating concentrations of Amylin, C-Peptide, Ghrelin, Gastric Inhibitory Peptide (GIP), Glucagon-Like Peptide (GLP)-1, Glucagon, IL-6, Insulin, Pancreatic Polypeptide (PP), Peptide YY, Tumor Necrosis Factor (TNF)-α by multianalyte profiling on the Luminex Magpix system (Luminex Technologies, Austin, USA.).

Time frame
Up to 5 years
3

Association between body mass index and sex steroids

Body mass index in in kg/m\^2. Sex steroids (including circulating total testosterone, estradiol, androstenedione, dehydroepiandrosterone-sulphate and estrone) measured by liquid chromatography tandem mass spectrometry (LC-MS/MS). Free testosterone will be calculated from total testosterone and sex hormone binding globulin levels.

Time frame
Up to 5 years
4

Association between percentage of fat mass with respect to total body weight and sex steroids

Fat mass% by bioelectric impedanciometry and DEXA. Sex steroids (including circulating total testosterone, estradiol, androstenedione, dehydroepiandrosterone-sulphate and estrone) measured by liquid chromatography tandem mass spectrometry (LC-MS/MS). Free testosterone will be calculated from total testosterone and sex hormone binding globulin levels.

Time frame
Up to 5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Lead sponsor

Instituto de Salud Carlos III

Collaborator

University of Alcala

Collaborator